SS-31 research guide
Mitochondria-targeting tetrapeptide
A research guide to SS-31/elamipretide naming, cardiolipin-related mechanisms, early human trials and the gap between mechanistic and clinical evidence.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
SS-31 is the research code commonly associated with elamipretide, a mitochondria-targeting tetrapeptide. Older publications may use MTP-131 or Bendavia. Alias mapping is useful for literature retrieval, but a batch still requires direct identity confirmation because a shared code name does not establish sequence, salt form or content.
02 · Evidence position
What the literature can support
Mechanistic studies describe interactions with mitochondrial membranes and cardiolipin. Early randomised human studies have examined specific disease settings, but the evidence is indication-specific and does not justify broad claims about energy, longevity or recovery.
03 · Study-level map
Evidence and its limits
What mechanism is commonly investigated?
Biophysical and cellular work reports SS-31 interactions with cardiolipin-rich mitochondrial membranes.
Limit: A proposed or measured molecular interaction does not by itself establish a clinical outcome.
Has it reached controlled human studies?
A small randomised, placebo-controlled ascending-dose trial evaluated a single infusion in heart failure with reduced ejection fraction.
Limit: The sample and exposure were limited; the authors called for further study of long-term safety and efficacy.
04 · Analytical context
Questions a batch record should answer
- 01Is the declared entity SS-31/elamipretide supported by intact-mass evidence and a stated counter-ion or salt form?
- 02Are aromatic oxidation products or truncated species assessed rather than hidden within total area purity?
- 03Is quantitative content reported separately from identity confirmation?
05 · Boundary conditions
What this record does not establish
- Mechanistic plausibility is not evidence for broad health or longevity claims.
- Human findings are tied to specific trial populations, formulations and endpoints.
- This dossier does not recommend use or extrapolate a laboratory vial to a medicine.
Sources checked
- 1.SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
PubMed / Journal of the American Society of Nephrology · 2013 · Primary study
- 2.Randomized, placebo-controlled trial of elamipretide in heart failure
PubMed / Circulation: Heart Failure · 2017 · Primary study